معرفی
Emmet McCormack is a Professor in Pharmaceutics and Pharmaceutical Technology at the Department of Clinical Science, University of Bergen, specializing in translational molecular imaging for cancer therapy development. His work bridges pharmaceutical technology with clinical oncology through advanced preclinical modeling.
His educational background includes a Ph.D. in Design, synthesis and in vitro evaluation of novel anti-cancer compounds from Trinity College Dublin (2002).
McCormack's research focuses on:
- Development of preclinical cancer models using bioluminescent imaging
- Nanoparticle-based drug delivery systems for targeted therapy
- Combination treatments for acute myeloid leukemia (AML) and solid tumors
- Pharmaceutical technology applications in oncology
Analysis of his 15 most recent publications reveals dominant themes in AML therapeutics, molecular imaging techniques, and nanoparticle drug delivery. Over 60% of his work centers on leukemia models, with significant contributions to pancreatic, ovarian, and breast cancer research through innovative imaging strategies and combination therapies.
His research program is supported by major competitive grants:
- SonoCURE: Sonoporation-Enhanced Therapy for Pancreatic Cancer (FRIPRO, Research Council of Norway)
- AML-VACCiN: Dendritic-cell vaccine therapy for AML (H2020 program)
- Personalized AML treatment guided by proteomics (Norwegian Cancer Society)
- Translational Development of Preclinical Models (Norwegian Cancer Society)
- ISPIC: Image-Guided Surgery and Immunotherapy (H2020 MSCA-ITN)
McCormack leads the Translational Molecular Imaging in Cancer group at Haukeland University Hospital, collaborating with clinical departments to develop image-guided therapeutic approaches for cancer patients.
